Preventing herpes zoster through vaccination: New developments

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIGURE 1
Rates of vaccination against herpes zoster in adults age 60 and older between 2007 and 2013.

TABLE 1

Clinical trials of herpes zoster (HZ) vaccines

	Shingles Prevention Study (SPS)²⁷	Short-Term Persistence Substudy³⁰	Long-Term Persistence Substudy³¹	Zostavax Efficacy and Safety Trial³³	ZOE-50⁵³
Intervention	0.5 ml of the live- attenuated Oka/ Merck VZV vaccine or placebo, subcutaneously	None	None	0.65 ml of the live-attenuated Oka/Merck VZV vaccine or placebo, subcutaneously	0.5 ml of recombinant VZV glyco-protein E and the AS01_B adjuvant system or placebo, intramuscularly
Number of injections	1			1	2.2 months apart
Number of participants	38.546	14.270 SPS participants	6.867 SPS participants from the vaccine group	22.439	16.160
Age, years	69 (median)	73.3 (mean)	74.5 (mean)	54.9 (mean)	623 (mean)
Mean duration of follow-up	3.13 years	Placebo: 0.98 years Vaccine: 1.36 years	3.74 years	1.3 years	3.2 years
Efficacy against HZ incidence	51.3%^a	39.6%^a	21.1%^a	69.8%^a	97.25^a
Efficacy against burden of illness	61.1%^a	50.1%^a	37.3^a	Not reported	Not reported
Efficacy against postherpetic neuralgia incidence	66.5%^a	60.1%	35.4^a	Not reported	Not reported
Injection-site adverse events	Placebo: 17% Vaccine: 48^a	Not applicable	Not applicable	Placebo: 14.4% Vaccine: 63.9%^a	Placebo: 12% Vaccine: 82%^a
Serious adverse events	Placebo: 1.3% Vaccine: 1.9%^a	Not applicable	Not applicable	Placebo: 0.5% Vaccine: 0.6%	Placebo: 8.9% Vaccine: 9.0%